Astellas receives permanent J-code for avacincaptad pegol for geographic atrophy

Iveric Bio, An Astellas Company, announced the U.S. Centers for Medicare and Medicaid Services (CMS) has assigned a unique, permanent Healthcare Common Procedure Coding System (HCPS) J-code for IZERVAY (avacincaptad pegol intravitreal solution) for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The new J-code, J2782, is effective April 1, 2024.

“Geographic atrophy is a progressive disease that can lead to irreversible vision loss and early treatment can have a significant impact on patients’ lives. Receiving a permanent J-code in the U.S. supports our efforts to increase timely patient access to IZERVAY, the first and only FDA approved GA treatment to demonstrate a statistically significant reduction in the rate of GA progression in just 12 months across two pivotal trials,” said Michael Petroutsas, Head of US Commercial, in a press release.

Since its U.S. launch in September 2023, more than 40,000 IZERVAY vials have been distributed to physician practices. The permanent J-code for IZERVAY is expected to accelerate patient access in the U.S. and has been published on the CMS website.

Read the full press release here.

This content is independent editorial sponsored by Astellas. Astellas had no input in the development of this content.